(Q44736592)

English

Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

quality of life

1 reference

based on heuristic

0 references

metastatic melanoma

1 reference

based on heuristic

author name string

Gwendoline M Kiebert

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Deborah L Jonas

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Mark R Middleton

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

language of work or name

1 reference

based on heuristic

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Cancer Investigation

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

821-829

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Current treatment options for malignant melanoma

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025084

21 January 2018

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025084

21 January 2018

Recommendations on health-related quality of life research to support labeling and promotional claims in the United States

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025084

21 January 2018

The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025084

21 January 2018

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025084

21 January 2018

Differences in perception of quality of life issues between health professionals and patients with pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025084

21 January 2018

Symptom and quality of life survey of medical oncology patients at a veterans affairs medical center: a role for symptom assessment

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025084

21 January 2018

The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025084

21 January 2018

Health-related quality-of-life assessment in clinical trials of supportive care in oncology

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025084

21 January 2018

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025084

21 January 2018

Oral chemotherapy: rationale and future directions

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025084

21 January 2018

Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025084

21 January 2018

Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025084

21 January 2018

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120025084

21 January 2018

Identifiers

10.1081/CNV-120025084

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

release_opzfac72lfh5jpbl65inlvi5gi

1 reference

https://api.fatcat.wiki/v0/release/opzfac72lfh5jpbl65inlvi5gi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44736592&oldid=2035614226"